E-LIB Suche - Ergebnisse für: Siegel, C A

1

BOC.04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLO..:

Sands, B.E. ; D'haens, G. ; Clemow, D.B....
Digestive and Liver Disease. 56 (2024) - p. S121-S122 , 2024

Link: https://doi.org/10.1016/..

2

P978 Changing therapy to achieve endoscopic healing in asym..:

Systrom, H ; Rai, V ; Singh, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1773-i1773 , 2024

Link: https://doi.org/10.1093/..

3

DOP76 Individual and comprehensive symptom resolution after..:

Tinoco da Silva Torres, J ; Panés, J ; Siegel, C A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i214-i215 , 2024

Link: https://doi.org/10.1093/..

4

P932 Corticosteroid-sparing effect of mirikizumab for the t..:

Laharie, D ; Siegel, C ; Dulai, P...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1697-i1698 , 2024

Link: https://doi.org/10.1093/..

5

P1177 Perceptions of patients with Inflammatory Bowel Disea..:

Bravo, A ; Christensen, S G ; Julsgaard, M...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i2100-i2100 , 2024

Link: https://doi.org/10.1093/..

6

P477 Performance of bowel preparation quality scales in pat..:

Solitano, V ; Siegel, C A ; Korzenik, J R...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i956-i957 , 2024

Link: https://doi.org/10.1093/..

7

OC.07.3: CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MOD..:

Laharie, D. ; Siegel, C.A. ; Samaan, K....
Digestive and Liver Disease. 56 (2024) - p. S163-S164 , 2024

Link: https://doi.org/10.1016/..

8

DOP16 Safety of long-term ozanimod treatment for up to 4 ye..:

Siegel, C ; Danese, S ; Rubin, D T...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i100-i101 , 2024

Link: https://doi.org/10.1093/..

9

OC.07.7: SUSTAINED IMPROVEMENT IN INFLAMMATORY BOWEL DISEAS..:

Sands, B.E. ; Feagan, B.G. ; Armuzzi, A....
Digestive and Liver Disease. 56 (2024) - p. S166 , 2024

Link: https://doi.org/10.1016/..

10

P551 Benefit–risk trade-offs and patient preferences for th..:

Gisbert, J P ; Schreiber, S ; Siegel, C A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1084-i1086 , 2024

Link: https://doi.org/10.1093/..

11

P631 Long-term safety of vedolizumab versus other biologic ..:

Louis, E ; Sebastien, S ; Siegmund, B...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i762-i763 , 2023

Link: https://doi.org/10.1093/..

12

P714 Mucosal healing in CD with vedolizumab versus other bi..:

Siegel, C ; Sebastian, S ; Siegmund, B...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i844-i844 , 2023

Link: https://doi.org/10.1093/..

13

DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-C..:

Feagan, B G ; Sands, B ; Siegel, C A...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i162-i164 , 2023

Link: https://doi.org/10.1093/..

14

P433 Efficacy of risankizumab by baseline clinical, biochem..:

Panaccione, R ; D'Haens, G ; Seenan, J P...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i560-i560 , 2023

Link: https://doi.org/10.1093/..

15

P185 Global perception of normal life by healthcare profess..:

Van Oostrom, J ; Anjie, S ; Braad, M...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i337-i339 , 2023

Link: https://doi.org/10.1093/..